Immunogenicity of the Foldon trimerization domain and efforts to shield it
PLOS One · 13.11.2026 · 21 (11) · e0362571
DOI: 10.1371/journal.pone.0362571 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 13.11.2026. Verfasst von John V Dzimianski und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomolecular Engineering, University of California Sant Cruz, Santa Cruz, California, United States of America. Hauptthemen laut MEDLINE: Hemagglutinin Glycoproteins, Influenza Virus, Viral Fusion Proteins. Die Arbeit nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NIAID NIH HHS, Division of Intramural Research, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Protein subunit and mRNA vaccines encoding viral glycoprotein antigens fused to the bacteriophage T4 fibritintrimerization domain are increasingly being tested in human clinical trials. AREXVY and ABRYSVO ® , subunit vaccines composed of respiratory syncytial virus (RSV) prefusion F glycoprotein(s) fused to Foldon, are now FDA-approved and regularly administered. However, administration of vaccine antigens containing the Foldon domain has the potential to elicit off-target antibody responses. Here, we demonstrate that protein subunit vaccine antigens RSV F Foldon and influenza hemagglutinin (HA) Foldon elicit antibodies against the Foldon domain. To dampen Foldon-induced antibody responses, we engineered influenza computationally optimized broadly reactive antigen (COBRA) HA proteins with N-glycosylation motif mutations at three different sites in Foldon. Mass spectrometry analyses confirmed partial occupancy of N-glycosylation modifications at two of the three intended sites. Two of the three COBRA HA Foldon mutant antigens demonstrated reduced binding by anti-Foldon monoclonal and polyclonal antibodies compared to the wild-type COBRA HA Foldon. However, mice immunized with the COBRA HA Foldon mutant antigens did not have a significant reduction in the elicitation of anti-Foldon antibodies. Further analysis suggested that some of the observed differences in antibody binding to mutant Foldon antigens can be attributed to differences in protein sequence alone. Altogether, these data suggest that while the N-glycosylation modifications may partially shield the Foldon from reactive antibodies, this shielding does not significantly reduce its immunogenicity in a naïve setting. Importantly, these data highlight that the Foldon trimerization domain is immunogenic, which should be considered during clinical trials of vaccines that contain Foldon.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biomolecular Engineering, University of California Sant Cruz, Santa Cruz, California, United States of America.
- Center for Vaccines and Immunology, College of Veterinary Medicine, University of Georgia, Athens, Georgia, United States of America.
- Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, Georgia, United States of America.
- Florida Research and Innovation Center, Cleveland Clinic, Cleveland, Ohio, United States of America.
- Department of Biochemistry and Molecular Biology, Franklin College of Arts and Sciences, University of Georgia, Athens, Georgia, United States of America.
- Department of Biomedical Sciences, College of Medicine, Florida State University, Tallahassee, Florida, United States of America.
ORCID-Profile: John V Dzimianski, Spencer R Pierce, Sara M O'Rourke, Rebecca M DuBois
Förderung
- NIH HHS
- NIAID NIH HHS
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases
Zitieren
APA
Dzimianski, J. V., Pierce, S. R., O'Rourke, S. M., Kunkel, I., Delgado-Cunningham, K., Gingerich, A. D., Mousa, J. J., Ross, T. M., & DuBois, R. M. (2026). Immunogenicity of the Foldon trimerization domain and efforts to shield it. PLOS One, 21(11), e0362571. https://doi.org/10.1371/journal.pone.0362571
Vancouver
Dzimianski JV, Pierce SR, O'Rourke SM, Kunkel I, Delgado-Cunningham K, Gingerich AD, et al. Immunogenicity of the Foldon trimerization domain and efforts to shield it. PLOS One. 2026;21(11):e0362571. doi:10.1371/journal.pone.0362571
BibTeX
@article{Dzimianski2026,
author = {Dzimianski, John V and Pierce, Spencer R and O'Rourke, Sara M and Kunkel, Ian and Delgado-Cunningham, Kevin and Gingerich, Aaron D and Mousa, Jarrod J and Ross, Ted M and DuBois, Rebecca M},
title = {Immunogenicity of the Foldon trimerization domain and efforts to shield it},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {11},
pages = {e0362571},
doi = {10.1371/journal.pone.0362571}
}
EUVIMED